179 related articles for article (PubMed ID: 20605972)
1. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
Ye L; Santarpia L; Gagel RF
Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
3. Endocrine tumors.
Averbuch SD
Cancer Chemother Biol Response Modif; 1991; 12():491-508. PubMed ID: 1681844
[No Abstract] [Full Text] [Related]
4. Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.
Ye L; Santarpia L; Gagel RF
Endocr Pract; 2009; 15(6):597-604. PubMed ID: 19546050
[TBL] [Abstract][Full Text] [Related]
5. Endocrine tumors as part of inherited tumor syndromes.
Zhang Y; Nosé V
Adv Anat Pathol; 2011 May; 18(3):206-18. PubMed ID: 21490438
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
[TBL] [Abstract][Full Text] [Related]
7. New targets and therapeutic approaches for endocrine malignancies.
Fassnacht M; Kreissl MC; Weismann D; Allolio B
Pharmacol Ther; 2009 Jul; 123(1):117-41. PubMed ID: 19374919
[TBL] [Abstract][Full Text] [Related]
8. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
9. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
11. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
12. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
Jimenez C; Habra MA; Huang SC; El-Naggar A; Shapiro SE; Evans DB; Cote G; Gagel RF
J Clin Endocrinol Metab; 2004 Aug; 89(8):4142-5. PubMed ID: 15292360
[TBL] [Abstract][Full Text] [Related]
14. Endocrine tumours.
Lamberts SW
Cancer Chemother Biol Response Modif; 1997; 17():492-503. PubMed ID: 9551228
[No Abstract] [Full Text] [Related]
15. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
18. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
19. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S;
Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580
[TBL] [Abstract][Full Text] [Related]
20. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
